Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.

The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into mult | ...

Q2 2025 Management View CEO Reshma Kewalramani highlighted "very strong performance across the board, growing and diversifying revenue with multiple new product launches," noting $2.96 billion in ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

Vertex stock nose-dived Tuesday after the biotech company said it wouldn't advance its next-generation pain drug into ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...

NEW YORK, NY-Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, has been named one of the 100 Most Powerful ...

The experimental drug is similar to the Boston-based company’s recently approved pill Journavx but could potentially be given ...

Vertex Pharmaceuticals Inc.’s bad news from a phase II pain study and separately on the regulatory front caused shares ...

Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...